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Background: Postoperative pancreatic ﬁstula formation (POPF) remains one of the most common and
detrimental complications following pancreaticojejunostomy (PJ). The aim of this meta-analysis is
to analyze the efﬁcacy of external pancreatic duct stent placement in preventing POPF formation
following PJ.
Methods: The primary end-point was the incidence of POPF formation following pan-
creaticoduodenectomy (PD) in the presence and absence of external stent placement. Secondary out-
comes examined were the incidence of perioperative mortality, delayed gastric emptying, postoperative
wound infection, operative time, blood loss, and length of hospital stay.
Results: Four trials were included comprising 416 patients. External pancreatic duct stenting was found
to reduce the incidence of both any grade POPF formation (OR 0.37, 95% CI ¼ 0.23 to 0.58, p ¼ 0.0001) and
clinically signiﬁcant (grade B or C) POPF formation (OR 0.50, 95% CI ¼ 0.30 to 0.84, p ¼ 0.0009) following
PD. The use of an external stent was also found to signiﬁcantly lessen length of hospital stay (SMD 0.39,
95% CI ¼ 0.63 to 0.15, p ¼ 0.001).
Conclusions: This analysis has shown that external pancreatic duct stenting is indeed efﬁcacious in the
incidence of both any grade as well as clinically signiﬁcant POPF formation following PD. Length of
hospital stay was also found to be signiﬁcantly less by external duct stenting.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The National Cancer Institute has estimated that there will be as
many as 45,220 new cases of pancreatic cancer in the U.S. in 2012
and that as many as 38,460 patients will die of the disease this year
alone [1]. Pancreaticoduodenectomy (PD) remains the sole poten-
tially curative intervention for several types of peri-ampullary and
pancreatic carcinomas and pathologies. Postoperative pancreaticSuite 310, Tampa, FL 33613,
el), prashantsukharamwala@
by Elsevier Ltd. All rights reservedﬁstula formation (POPF) as a result of pancreaticojejunostomy (PJ)
anastomotic failure remains one of the most serious and dreaded
complications following PD. POPF is believed to be consequence of
pancreatic exocrine secretion seepage across a compromised
anastomotic site, with the most likely mechanism being autodi-
gestion and destruction of the tissue surrounding the PJ anasto-
motic site leading to dehiscence and seepage into the abdominal
cavity. The release of these activated pancreatic juices then cause
peripancreatic collections, intra-abdominal abscesses, hemorrhage,
and POPF [2].
Protection of this anastomotic site has therefore been the focus
of many modiﬁcations to the original Whipple procedure. Stent
placement across the PJ anastomosis has been proposed to protect.
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secretions of the pancreatic remnant away from the delicate
anastomotic site. In addition, such stents have been theorized to
promote precise placement of anastomotic sutures, facilitate
decompression of the pancreatic remnant, and maintain patency of
the pancreatic duct postoperatively [3,4].
Two similar, though uniquely different, procedures have been
integrated into the traditional PD procedurewith varying reports of
actual efﬁcacy; an internal and an external pancreatic duct stent.
The internal stent technique is generally performed by inserting a
6 cm stent into the pancreatic duct such that one-half of its length
remains within the duct itself, bridges across the anastomotic site,
and empties into the jejunal lumen. In contrast, the external stent
utilizes a longer stent placed similarly within the pancreatic duct
stump, bridges across the anastomotic site into the jejunal lumen,
but the tail of which is exited through a small enterotomy site in the
free end of the jejunal loop. This is then closed with a purse-string
suture, externalized via a stab incision in the anterior abdominal
wall, and closed by suturing the serosa of the jejunum to the
peritoneum of the abdominal wall [6e9]. In both cases migration of
the catheter is prevented with an absorbable suture attachment to
the jejunal mucosal surface [4,5]. The ﬁnal PJ reconstruction is then
carried out with an end-to-side, duct-to-mucosa anastomosis using
1- or 2-layer interrupted ﬁne sutures [6].
A previous meta-analysis performed by Markar et al. [10]
examined the combined effect of placement of either stent type
on clinical outcome following PJ. Based on the integrated data sets,
these authors identiﬁed a non-statistically signiﬁcant trend to-
wards reduced pancreatic ﬁstula with the use of either stent
method, but the data was unable to deﬁnitively rule out the null
hypothesis that stenting had no beneﬁcial effect. Given the unique
mechanism and distinctive risk and reward proﬁles of each indi-
vidual technique, these results may have been affected by co-
intervention bias as described by Kelly et al. [11].
The purpose of the present meta-analysis was to determine
whether the technique of externalizing the pancreatic duct stent is
indeed efﬁcacious in minimizing the incidence of postoperative
morbidity and mortality, including POPF formation, versus no stent
placement following PJ.2. Methods
An electronic literature search was conducted among all articles
from January 1970 to March 2012. Medline, Cochrane Library, SCI,
and EMBASE were searched using the following text and keywordsTable 1
Baseline and intraoperative demographics.
Kuroki et al. (2011) [14]
Number of patients Stent 23
No stent 22
Age Stent 68.1 ± 11.2
No stent 68.2 ± 8.4
Male/Female Stent 13/10
No stent 12/10
BMI Stent 21.0 ± 3.0
No stent 21.9 ± 3.0
Pancreatic duct size Non-dilated (<3 mm) 35
Dilated (>3 mm) 10
Pancreatic texture Soft 45a
Hard 22a (excluded)
Jadad's score [12] 3
NR: not reported.
a Kuroki et al. differentiated soft from hard pancreata utilizing a time-signal intensity
(MRI).in combinationwith bothmedical subject headings (MeSH) and text
words: “Whipple procedure”, “pancreatoduodenectomy”, “pancre-
atic ﬁstula”, and “pancreaticojejunostomy”. Further searches were
extended to Oncology journals from Asian, American and European
continents. In addition, bibliographies of included studies were
screened for any additional literature. Prospective randomized
control trials reporting primary outcomes on pancreatic ﬁstula and
mortality from stent versus non-stent during PJ were reviewed.
2.1. Inclusion criteria
Studies included in this analysis were those that were pro-
spective randomized control in nature and that reported POPF
formation or at least one of the secondary outcomes of interest in
patients receiving an external pancreatic duct stent versus no stent
following PD.
2.2. Exclusion criteria
Studies were excluded from this study if they included non-
randomized control trials, utilized an internal pancreatic duct
stent technique, those in which the outcomes of interest were
impossible to calculate from the published results, or those in
which the standard deviation of the mean for continuous outcomes
of interest (operative time, blood loss, and length of hospitaliza-
tion) were not reported.
2.3. Assessment of study quality
The quality of the randomized control trials included in this
study was assessed using the Jadad scoring system [12], which was
based upon three criteria; 1) randomization of cohorts, 2) double-
blind assessment, and 3) accountability for patients either not
included or withdrawn from the study (Table 1). Also quality
guidelines were adherent to PRIMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) statements in order to
increase transparency of conclusions made by the authors [13].
Methodological qualities were independently assessed and any
discrepancies were resolved with detailed discussion. A PRISMA
ﬂow chart was also obtained (Fig. 1).
2.4. Outcomes of interest
The primary outcome of interest was the incidence of POPF
formation following PD in the presence versus absence of externalMotoi et al. (2012) [7] Pessaux et al. (2001) [9] Poon et al. (2007) [6]
47 77 60
46 81 60
66.0 (33e79) 60.8 ± 11.8 61 ± 12
65.5 (32e80) 60.6 ± 11.8 62 ± 13
26/21 39/38 31/29
29/17 47/34 41/19
21.7 (14.3e32.4) 24.6 ± 4 NR
21.5 (16.3e29.3) 25.2 ± 4.7 NR
41 158 60
52 (excluded) 60
47 158 66
46 (excluded) 54
3 3 3
curve (TIC) based upon dynamic contrast-enhanced magnetic resonance imaging
Fig. 1. Study ﬂow diagram in accordance with QUOROM statement.
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were peri-operative mortality, delayed gastric emptying, operative
time and blood loss, and total length of hospital stay.
2.5. Statistical analysis
Data on the endpoint measures were entered into a digital
spreadsheet for analysis. Data analysis was performed utilizing the
freeware program Review Manager (RevMan, Version 5.1 for
Windows, Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2011). For dichotomous data, the Mantel-Hansel
method was utilized with a ﬁxed effect model and a 95% conﬁ-
dence interval. Dichotomous data results were considered to be
statistically signiﬁcant with a p value < 0.05 provided the 95%
conﬁdence interval did not include the value 1. For continuous data
reported asmean ± standard deviation, an inverse variancemethod
was used with a ﬁxed effect model and a 95% conﬁdence interval.
Continuous data results were considered to be statistically signiﬁ-
cant with a p value <0.05 provided the 95% conﬁdence interval did
not include the value 0. The data for the various outcomes was
entered into the RevMan software and Foster plots were generated
(Figs. 2 and 3).Fig. 2. Forest plot of overa3. Results
Similar to the previousmeta-analysis performed byMarker et al.
[10], preliminary electronic and manual searches returned 15 ar-
ticles matching the initial search criteria. Subsequent screening
resulted in four prospective randomized trials examining only
external pancreatic stents following PD [6,7,9,14]. Of note, the
present study excluded two trials previously included by Markar
et al. [10]; 1) the 2009 prospective trial conducted by Smyrniotis
et al. [5] on the basis that this study examined internal stents only,
and 2) the 2006 trial conducted byWinter et al. [4] on the basis that
internal stents were included and because these authors utilized an
alternating method of allocating patients to either treatment or
control arms, which may have inadvertently introduced selection
bias as described by Doll et al. [15] Baseline and intra-operative
demographics of the study populations are listed in Table 1.
All four trials reported on the incidence of POPF formation
following PD with versus without external pancreatic duct stent
placement [6,7,9,14]. There was a statistically signiﬁcant difference
in the overall incidence of any grade POPF formation among these
cohorts (OR 0.37, 95% CI ¼ 0.23 to 0.58, P ¼ 0.0001) as well as a
statistically signiﬁcant difference in the incidence of clinicallyll incidence of POPF.
Fig. 3. Forest plot of clinically signiﬁcant POPF.
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P ¼ 0.0009) favoring external stent placement (Table 2). Two trials
reported length of hospital stay among these two populations,
which was found to be statistically signiﬁcant favoring external
stent placement (SMD 0.39, 95% CI ¼ 0.63 to 0.15, P ¼ 0.001)
[6,9].
There was no signiﬁcant difference in the incidence of peri-
operative mortality (3 trials [6,7,9]: OR 0.86, 95% CI ¼ 0.27 to
2.73, P ¼ 0.80), delayed gastric emptying (3 trials [6,7,9]: OR 0.54,
95% CI¼ 0.29 to 1.01, P¼ 0.05), or postoperative wound infection (3
trials [6,7,9]: OR 0.77, 95% CI ¼ 0.38 to 1.56, P ¼ 0.047) between
external stent and non-stent groups. Likewise there was no sig-
niﬁcant difference in the total operative time (3 trials [6,9,14],
SMD0.12, 95% CI¼0.34 to 0.10, P¼ 0.29) or intraoperative blood
loss (3 trials [6,9,14], SMD 0.04, 95% CI ¼ 0.18 to 0.26, P ¼ 0.71)
identiﬁed.4. Discussion
POPF remains one of the most common and serious complica-
tions following pancreatic resection with PJ and is widely regarded
as the most ominous indication of clinical course. The two most
uniformly and deﬁnitively cited risk factors for developing POPF are
soft texture of the pancreatic remnant [14,15] and diameter of the
pancreatic duct stump [17]. This suggests that the integrity of the PJ
anastomosis and its susceptibility to failure is of critical importance
in preventing POPF. Thus, exclusion of pancreatic exocrine secre-
tions from the anastomotic site is essential.
The use of a stent to physically isolate the PJ anastomotic site
from pancreatic secretions while also providing a conduit for
pancreatic decompression is supported by several prospective
randomized trials. In a 2012 randomized control trial, Motoi et al.
found that the incidence of clinically signiﬁcant POPF was
decreased in the presence of an externalized pancreatic duct stent
(6.4% stented vs. 21.7% non-stented, P ¼ 0.04) [7]. Furthermore,
researchers noted that among patients with a non-dilated
pancreatic duct stump (3 mm) the incidence of clinicallyTable 2
Intra- and post-operative outcomes.
Number of studies
Pancreatic ﬁstula (any grade) with respect to stent 4 [6,7,9,14]
Clinically signiﬁcant (grade B or C) pancreatic
ﬁstula with respect to stent
4 [6,7,9,14]
Pancreatic ﬁstula with respect to duct diameter 2 [6,7]
Length of hospital stay 2 [6,9]
Perioperative mortality 3 [6,7,9]
Delayed gastric emptying 3 [6,7,9]
Postoperative wound infection 3 [6,7,9]
Total operative time 3 [6,9,14]
Intraoperative blood loss 3 [6,9,12]relevant POPF was signiﬁcantly lower in the external stent group
versus non-stented group (9.5% stented vs. 40% non-stented,
P ¼ 0.033). Among patients with a dilated (>3 mm) pancreatic
duct stump, however, the authors noted that the incidence of POPF
was equivocal (3.8% stented vs. 7.7%, P ¼ 1.0).
In 2011, Pessaux et al. [9] examined placement of an external
pancreatic duct stent only among high-risk patients, those with a
soft pancreatic remnant texture or a non-dilated pancreatic duct
(<3 mm). These researchers found that the incidence of POPF was
signiﬁcantly reduced among the stent group (26% stented vs. 42%
non-stented, P ¼ 0.034) and that the stented group had a signiﬁ-
cantly lower overall morbidity (41.5% vs. 61.7%, P ¼ 0.01), surgical
morbidity (35.1% vs. 55.5%, P ¼ 0.009), and delayed gastric
emptying (7.8% stented vs. 27.2% non-stented, P¼ 0.001) compared
to the non-stented group. In a similar 2007 randomized control
study, Poon et al. [6] found that external drainage of the pancreatic
duct signiﬁcantly reduced the incidence of POPF (6.7% stented vs.
20% non-stented, P¼ 0.032) and length of hospital stay (mean of 17
days stented vs. 23 days non-stented, P ¼ 0.039) following PJ.
Furthermore, they noted that the incidence of pancreatic ﬁstula
was reduced among stented patients with a non-dilated pancreatic
duct (14.3% stented vs. 25% non-stented, P¼ 0.349) as well as those
with a dilated pancreatic duct (3.1% stented vs. 10.7% non-stented,
P ¼ 0.257), though neither of these conclusions achieved statisti-
cal signiﬁcance.
However, several studies have refuted the utility of pancreatic
duct stenting in mitigating POPF. In 2011, Kuroki et al. [14] found no
signiﬁcant difference in the incidence of any grade POPF (34.5%
stented vs. 40.9% non-stented, P ¼ NS) or clinically signiﬁcant POPF
(21.7% stented vs. 27.3% non-stented, P¼NS) among patients with a
soft pancreatic remnant utilizing the external duct stent following
PD. This suggests that while a soft pancreatic texture is a well-
documented risk factor for POPF formation [15e19], pancreatic
duct stenting has no effect on mitigating that risk.
The meta-analysis performed here has demonstrated that
external pancreatic duct stent placement does signiﬁcantly reduce
the incidence of POPF and length of hospital stay following PD.Participants Odds ratio (MH, ﬁxed, 95% CI) Statistical difference
416 0.37 [0.23, 0.58] S (P ¼ 0.0001)
416 0.50 [0.30, 0.84] S (P ¼ 0.0009)
213 4.88 [1.97, 12.04] S (P ¼ 0.0006)
278 SMD 0.39 [0.63, 0.15] S (P ¼ 0.001)
371 0.86 [0.27, 2.73] NS (P ¼ 0.80)
371 0.54 [0.29, 1.01] NS (P ¼ 0.05)
371 0.77 [0.38, 1.56] NS (P ¼ 0.047)
323 SMD 0.12 [0.34, 0.10] NS (P ¼ 0.29)
323 SMD 0.04 [0.18, 0.26] NS (P ¼ 0.71)
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performed byMarkar et al. [10] in just one respect, that the external
stent method alone be considered, the conclusion that the external
stenting and not internal stenting is efﬁcacious in preventing POPF
is reasonable. However, this conclusion is in contrast to the unique
2010 prospective randomized controlled trial by Tani et al. [3],
which found that the speciﬁc type of drainage stent had no impact
on the overall incidence of postoperative complications including
POPF (26% internal vs. 20% external, P ¼ NS). This study was
hampered by a small sample size. Therefore, additional randomized
controlled trials studies comparing the efﬁcacy of internal versus
external pancreatic duct stenting is therefore warranted.
Taking into account both the meta-analysis performed here as
well as the breadth of literature summarized above, it is clear that
external pancreatic duct stenting does indeed reduce pancreatic
leakage leading to POPF, particularly among high-risk patients with
a non-dilated pancreatic duct 3 mm. At present, it appears that
this effect is not replicated among patients with a dilated (>3 mm)
pancreatic duct. Although the univariable analysis of several
studies have identiﬁed soft pancreatic texture as risk factor for the
development of POPF [4,6,7], stenting does not appear to mitigate
this risk in any signiﬁcant manner.
The trend observed that beneﬁcial results were found most
prominently among patients with a non-dilated pancreatic duct.
This supports the hypothesis that the mechanism of action is at
least in part due maintaining lumen patency and preventing
inﬂammation-related constriction and subsequent intraductal hy-
pertension, which would theoretically be more prevalent among
smaller duct sizes. This mechanism mimics those of endoscopically
placed pancreatic duct stents following ERCP for a variety of
pancreatic pathologies [20, 21].
The fact that only external stents demonstrated efﬁcacy in
preventing POPF or other related complications post-PJ supports
previous hypotheses that the longer external stents prevent either
premature stent migration or occlusion, which in theory may be
more prevalent with the shorter internal stent. The hypothesis
previously put forth by Biehl and Traverso [22], in their animal
models, that the stent acts as an instrument to assist in the precise
placement of sutures, and thereby facilitates a more effective PJ
anastomosis, is plausible given that smaller ducts are inherently
more difﬁcult to suture. However, should this be the predominant
mechanism of action, one would expect similar efﬁcacy among
both internal and external stents, which has not been shown to be
the case.
5. Conclusion
The results of this study have demonstrated a statistically sig-
niﬁcant reduction in the incidence of both any grade and clinically
signiﬁcant POPF following PJ using an external pancreatic duct
stent. This result afﬁrms the trend towards reduced pancreatic
ﬁstula utilizing pancreatic stents previously identiﬁed by Markar
et al. [10], though with the scope limited to just external stent
placement. In the context of all the available literature and trials to
date, it is our conclusion that placement of an external pancreatic
duct stent is efﬁcacious in preventing POPF and shortening hospital
stay among patients with a non-dilated (3 mm) pancreatic duct.
Further randomized controlled trials comparing external pancre-
atic duct stent versus no stent among patients with a non-dilated
pancreatic duct, with sub-group analysis of soft versus ﬁbrotic
pancreatic texture, is warranted to conﬁrm these conclusions.
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